Profund Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Profund Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,488	Closed	-$1.23M	–	1156
2023 Q1	$1.23M	Buy	+11,488	New	+$1.32M	0.08%	247

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Profund Advisors's RXDX Position: Q2 2023 in Review

Profund Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 11,488 shares — an estimated $1.23M sold.

Profund Advisors first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $1.23M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Profund Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Profund Advisors sold 11,488 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.23M.
Profund Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Profund Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $1.23M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.